Меню
Идёт набор NCT06736899

Trial of Orbital Atherectomy Versus Standard Strategy in Calcified Bifurcation Lesions

Без фазы С лечением Coronary Artery Disease Coronary Disease

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Orbital Atherectomy System Treatment, Balloon System Treatment.
Кому может быть актуально
Состояния в реестре: Coronary Artery Disease, Coronary Disease. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Испания
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Randomized Trial of Orbital Atherectomy Versus Standard Strategy in Calcified Bifurcation Lesions

Обзор

Clinical research with medical devices indicated in accordance with the CE marking, led by researchers, multicenter, open, prospective, randomized and controlled. Patients are randomized to treatment with a conventional balloon and then a coronary stent or to initial plaque modification with Orbital Atherectomy (OA) and then a coronary stent. To evaluate the efficacy and safety of OA in the adequate treatment with coronary stent of the calcified bifurcation lesion using angiography and optical coherence tomography (OCT).

Подробное описание

The risk profile of patients and their comorbidities have worsened and the observed lesions undergoing treatment are increasingly complex. This has promoted the development of new technologies for plaque modification, especially in the context of calcified lesions. These predispose to suboptimal results of the intervention due to an increased risk of malapposition and underexpansion of the stents, the main variables for restenosis and/or thrombosis of the stents. Thus, compared with non-calcified lesions, the increased amount of calcium in the coronary artery leads to a higher incidence of major adverse cardiac events (MACE).

Coronary bifurcation stenting remains complex and is associated with a high risk of stent thrombosis and restenosis even with contemporary techniques, and suboptimal outcomes are frequently observed due to side branch (SL) involvement that increases cardiovascular events.

Our hypothesis is that the use of orbital atherectomy (OA) for coronary revascularization in the presence of calcified bifurcation lesions is feasible and safe compared to the more common technique, favoring the subsequent performance of provisional stenting (PS).

Вмешательства

  • Устройство Orbital Atherectomy System Treatment
    Percutaneous coronary intervention of a calcified bifurcation coronary lesion with balloon angioplasty followed by drug eluting stent. Selection of balloon type is at operator´s discretion. Baseline and post dilation OCT will be performed.
  • Устройство Balloon System Treatment
    Percutaneous coronary intervention of a calcified bifurcation coronary lesion with Orbital Atherectomy followed by drug eluting stent. Baseline and post dilation OCT will be performed.

Первичные конечные точки

  • EFFICACY: Angiographic criteria success [Срок оценки: At the end of PCI (Percutaneous Coronary Intervention)]
  • EFFICACY: OCT criteria: Stent expansion [Срок оценки: At the end of PCI]
Вторичные конечные точки (8)
  • SAFETY:Major adverse cardiac events (MACE) [Срок оценки: 12 months]
  • SAFETY:Major adverse cardiac events (MACE) [Срок оценки: 6 months]
  • SAFETY:Major adverse cardiac events (MACE) [Срок оценки: 30 days]
  • SAFETY:Major adverse cardiac events (MACE) [Срок оценки: At the end of PCI]
  • EFFICACY: Other variables related to stent expansion. Minimal Lumen Area (MLA) in mm2 [Срок оценки: At the end of PCI]
  • EFFICACY: Other variables related to stent expansion. Minimal Lumen Area (MLA) [Срок оценки: At the end of PCI]
  • EFFICACY: Other variables related to stent expansion. Mean stent expansion [Срок оценки: At the end of PCI]
  • EFFICACY: Other variables related to stent expansion. Stent expansion using linear model [Срок оценки: At the end of PCI]

Критерии участия

Критерии включения

  • Patients over 18 years of age and
  • Patients with moderately or severely calcified bifurcation lesions (lateral vessel ≥ 2mm), candidates for PCI with coronary stent implantation, in whom there is the possibility of adequate clinical follow-up at 1 year and
  • Patients agree to participate in the study, by signing the Informed Consent.

Критерии исключения

  • Patients with revascularization of the artery to be treated within 9 months prior to the index procedure.
  • Patients with contraindication for the use of Orbital Atherectomy:
  • Patients in cardiogenic shock.
  • Patients with Thrombotic lesions.
  • Patients with Vascular graft disease.
  • Patients with remain vessel disease.
  • Patients with severe left ventricular dysfunction.
  • Patients allergic to the components of the washing serum (glide).
  • Patients with life expectancy less than one year.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

Испания · 9 центров
  • H. G.U. de ALICANTE DR. BALMIS — Alicante
  • Hospital Del Mar — Barcelona
  • H. de La Santa Creu I Sant Pau — Barcelona
  • Hospital Universitario Reina Sofia — Córdoba
  • Hospital Universitario La Paz — Fuencarral-El Pardo
  • Hospital Universitario Lucus Augusti — Lugo
  • Hospital Universitario La Luz — Madrid
  • Hospital Universitari de Salamanca — Salamanca
  • … и ещё 1 центр

Публикации

  • Parikh K, Chandra P, Choksi N, Khanna P, Chambers J. Safety and feasibility of orbital atherectomy for the treatment of calcified coronary lesions: the ORBIT I trial. Catheter Cardiovasc Interv. 2013 Jun 1;81(7):1134-9. doi: 10.1002/ccd.24700. Epub 2013 Mar 5. PMID 23460596
  • Burzotta F, Louvard Y, Lassen JF, Lefevre T, Finet G, Collet C, Legutko J, Lesiak M, Hikichi Y, Albiero R, Pan M, Chatzizisis YS, Hildick-Smith D, Ferenc M, Johnson TW, Chieffo A, Darremont O, Banning A, Serruys PW, Stankovic G. Percutaneous coronary intervention for bifurcation coronary lesions using optimised angiographic guidance: the 18th consensus document from the European Bifurcation Club. PMID 38752714
  • den Dekker WK, Siskos AA, Wilschut JM, Nuis RJ, Scarparo P, Neleman T, Masdjedi K, Ligthart JMR, Diletti R, Daemen J, Van Mieghem NM. Initial experience with orbital atherectomy in a tertiary centre in the Netherlands. Neth Heart J. 2023 May;31(5):196-201. doi: 10.1007/s12471-022-01742-3. Epub 2022 Dec 12. PMID 36507948
  • Donatelle M, Agasthi P, Parise H, Igyarto Z, Martinsen BJ, Leon MB, Beohar N. Coronary Orbital Atherectomy in Patients With Severe Aortic Stenosis. J Invasive Cardiol. 2022 Oct;34(10):E696-E700. doi: 10.25270/jic/22.00066. PMID 36200995
  • Jurado-Román A, Gómez-Menchero A, Gonzalo N, et al. Plaque modification techniques to treat calcified coronary lesions. Position paper from the ACI-SEC. REC Interv Cardiol Engl Ed. Published online February 7, 2023:9672. doi:10.24875/RECICE.M22000345

Идентификаторы

NCT: NCT06736899 · EPIC44-OraBil

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗